Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Anticoagulation

Phase 1Small molecule

HHospital Álvaro Cunqueiro

Anticoagulation is one of 95 small molecule programs targeting Portal vein thrombosis. It is currently in Phase 1.

5

Indications

8

Total Trials

1

Active Trials

94

Competitors

Pipeline

Status by Indication[3][1]

Indication

Portal Vein ThrombosisActive, not recruiting

Pulmonary EmbolismActive, not recruiting

PregnancyRecruiting

Atrial FibrillationActive, not recruiting

Pulmonary Embolism AcuteCompleted

Portal Vein ThrombosisPreclinical

Active, not recruiting

Pulmonary EmbolismPreclinical

Active, not recruiting

PregnancyPhase 1

Recruiting

Atrial FibrillationPreclinical

Active, not recruiting

Pulmonary Embolism AcutePreclinical

Completed

Competition

Competitive Landscape

136 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Calquence

Anticoagulation

HHospital Álvaro Cunqueiro

Rituxan

Coumadin

Brukinsa

BBeOne Medicines

Imbruvica

PPharmacyclics LLC.

Versed

CConrado Roberto Hoffmann Filho

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Romazicon

CConrado Roberto Hoffmann Filho

Statin

Bristol-Myers Squibb

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Pregnancy

NCT04976465

Clinical

Trials by Indication[1]

Pregnancy1 trial

Treatment and Clinical Outcomes Among SLE Patients in Pregnancy

Recruiting·QQilu Hospital of Shandong University·Phase 1·NCT04976465·200 enrolled

Anticoagulation1 trial

Management of Patients on Long Term Anticoagulation Therapy Undergoing a Primary Total Hip of Knee Replacement

Unknown status·AAssociation pour le Développement et l'Enseignement de la Chirurgie Réparatrice et Orthopédique··NCT02714673·600 enrolled

Portal vein thrombosis1 trial

TIPS vs Endoscopic Therapy for Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis

Unknown status·—·N/A·NCT02485184·120 enrolled

Venous thrombosis1 trial

Catheter-directed Thrombolysis Compared to Anticoagulation Alone for Acute Primary Iliofemoral Deep Venous Thrombosis

Withdrawn·UUniversity of Toledo Health Science Campus·Phase 4·NCT04411316

Stroke1 trial

ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial

Completed·UUMC Utrecht·Phase 4·NCT00161070·4,500 enrolled

3 more indications

Atrial Fibrillation1 trial

Retrospective Observational Registry of Patients With Atrial Fibrillation From Vigo´s Health Area

Unknown status·HHospital Álvaro Cunqueiro··NCT04364516·15,000 enrolled

Oral Anticoagulation1 trial

Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation

Unknown status·DDeutsches Herzzentrum Muenchen·Phase 4·NCT00776633·614 enrolled

Pulmonary Embolism Acute1 trial

STORM-PE: A Prospective, Multicenter, Randomized Controlled Trial Evaluating Anticoagulation Alone vs Anticoagulation Plus Mechanical Aspiration With the Indigo® Aspiration System for the Treatment of Intermediate High Risk Acute Pulmonary Embolism

Completed·PPenumbra Inc.·Preclinical·NCT05684796·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Anticoagulation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anticoagulation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anticoagulation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospital Álvaro Cunqueiro company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: HHospital Álvaro Cunqueiro

Related News